CA3123605A1 — Peanut oral immunotherapy dosing schedule for missed doses
Assigned to Societe des Produits Nestle SA · Expires 2020-06-25 · 6y expired
What this patent protects
The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. In certain embodiments, the disclosure provides methods for continuing an oral immunotherapy for the treatment of a peanut allergy after missing a scheduled oral administration of o…
USPTO Abstract
The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. In certain embodiments, the disclosure provides methods for continuing an oral immunotherapy for the treatment of a peanut allergy after missing a scheduled oral administration of one or more consecutive doses of a pharmaceutical composition comprising peanut protein.
Drugs covered by this patent
- Xifaxan (rifaximin) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.